INTS Intensity Therapeutics
- 5.070
- +0.070+1.40%
- 5.070
- 0.0000.00%
Intensity Therapeutics News
Benchmark: Reiterates Intensity Therapeutics (INTS.US) rating and adjusted from Speculative Buy to Specified Buy with a target price of $12.00.
Benchmark: Reiterates Intensity Therapeutics (INTS.US) rating and adjusted from Speculative Buy to Specified Buy with a target price of $12.00.
Intensity Therapeutics Expands Board, Welcomes New Audit Director
Intensity Therapeutics Announces the Appointment of Thomas Dubin to Its Bd of Directors
Intensity Therapeutics Announces the Appointment of Thomas Dubin to Its Bd of Directors
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Intensity Therapeutics Q1 EPS $(0.34) Up From $(0.39) YoY
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.34) per share. This is a 12.82 percent increase over losses of $(0.39) per share from the same period last year.
Intensity Therapeutics 1Q Loss/Shr 34c >INTS
Intensity Therapeutics 1Q Loss/Shr 34c >INTS
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer
Intensity Therapeutics | 10-Q: Quarterly report
Intensity Therapeutics Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Intensity Therapeutics Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) Shares
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics with a Speculative Buy and maintains $12 price target.
Intensity Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 130.77% Benchmark → $12 Reiterates Speculative Buy → Speculative Buy 11/14/2023 130.77% Benchma
Intensity Therapeutics Reports FY23 EPS $(1.38) Vs $(2.22) YoY
Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for the same period in 2022. The decrease was primaril
Intensity Therapeutics 2023 Year-End Cash And Investments $14.8M
Intensity Therapeutics 2023 Year-End Cash And Investments $14.8M
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.
12 Health Care Stocks Moving In Monday's Intraday Session
GainersRegencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares in
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) shares increased by 69.4% to $1.46 during Wednesday's pre-market session. The market value of their outstanding shares is at $31.9 million. Creative Medical Tech (NA
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry to turn "cold" tumors "hot" by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor.
Intensity Therapeutics Unveils New Incentive Compensation Plan
Analysis
Price Target
No Data
